(Q38195796)

30 August 2017

1 reference

title

Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide (English)

1 reference

30 August 2017

1 reference

Mahmoud R Gaballa

1 reference

30 August 2017

Emmanuel C Besa

series ordinal

1 reference

30 August 2017

publication date

14 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

1 reference

30 August 2017

page(s)

723-733

1 reference

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Genetic deletions in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Treatment of the 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

The role of haploinsufficiency of RPS14 and p53 activation in the molecular pathogenesis of the 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Cell biology: Arrest by ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

S6-haploinsufficiency activates the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Genomic instability--an evolving hallmark of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

The 5q- syndrome: biology and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Role of lenalidomide in the treatment of myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Biology and treatment of the 5q- syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Deregulation of microRNAs in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

How we treat higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Combination strategies in myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2022-3

10.1007/S00277-014-2022-3

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference